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Abstract Platelet aggregation is accompanied by the tyrosine
phosphorylation of several proteins including syk. However,
some of these proteins are not identified. Recent studies showed
that LAT is a syk substrate and is tyrosine phosphorylated
during T cell stimulation. In this study, we demonstrated that
LAT is present in platelets and is tyrosine phosphorylated in
response to ADP- and thrombin-stimulated aggregation. More-
over, LAT, like syk and L3, translocates to the cytoskeleton
during the late stage of thrombin-stimulated irreversible
aggregation and not during ADP-stimulated reversible aggrega-
tion.
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1. Introduction
Platelet aggregation is critical for hemostasis and thrombo-
sis. Aggregation of platelets is mediated by the binding of
¢brinogen to its integrin receptor KIIbL3 when platelets are
activated by agonists such as ADP, thrombin or collagen
[1]. Platelet aggregation results in tyrosine phosphorylation
and activation of several known proteins including syk tyro-
sine kinase. However, some of these tyrosine-phosphorylated
proteins remain to be identi¢ed [1]. The tyrosine phosphoryl-
ation pro¢le of proteins is markedly reduced in thrombas-
thenic platelets, which do not aggregate [1], which indicates
that tyrosine phosphorylation might play a critical role in
platelet signaling.
LAT is a 36^38-kDa transmembrane protein recently
cloned from T cells [2]. LAT is a substrate of syk and ZAP-
70 in T cells and is tyrosine-phosphorylated in response to T-
cell stimulation. LAT is critical for T-cell signaling as two
tyrosine to phenylalanine mutations in LAT signi¢cantly in-
hibit T-cell signaling [2]. LAT is not present in B cells, making
it a cell speci¢c signaling molecule. Since platelets, like T and
B cells, are of hematopoietic origin, we were curious to see
whether LAT is one of the unidenti¢ed tyrosine-phosphoryl-
ated proteins in platelets.
Cytoskeletal rearrangement is necessary for platelet aggre-
gation. A recent study di¡erentiated ADP-mediated reversible
aggregation from thrombin-mediated irreversible aggregation
in terms of di¡erential translocation of signaling molecules [3].
They observed that RhoA did not translocate to the cytoske-
leton during ADP-mediated reversible aggregation, but trans-
locates during thrombin-stimulated irreversible aggregation
[3]. RhoA is a member of the Ras family of small GTPases
and is known to take part in cytoskeletal rearrangement [4].
These results correlate translocation of signaling molecules
with reversible and irreversible aggregation, which are de-
pendent on the di¡erential rearrangement of the cytoskeleton.
Thus, the use of ADP and thrombin as agonists under the
conditions of reversible and irreversible aggregation could be
very useful in identifying translocation of other signaling mol-
ecules. We wanted to see whether LAT translocates to the
cytoskeleton during platelet aggregation in response to ADP
and thrombin stimulation.
Results presented in this paper show that LAT is present in
platelets and it is tyrosine phosphorylated during both ADP-
or thrombin-stimulated platelet aggregation. Furthermore,
this study documents that the translocation of LAT during
thrombin-stimulated irreversible aggregation di¡ers from that
during ADP-stimulated reversible aggregation. Interestingly,
L3 and syk showed a similar pattern of translocation. The
possible implications of these observations are discussed.
2. Materials and methods
2.1. Materials
Monoclonal antibody to L3, AP-3, used for immunoprecipitation,
was obtained from the previously described cell line supplied by Dr.
Peter J. Newman, Blood Institute, Milwaukee, WI, USA [5]. Polyclo-
nal antibody to L3 called Fire and Ice, used for Western analysis, was
a gift from Dr. Peter J. Newman [6]. The polyclonal antibodies to
LAT and syk used in Western analysis or immunoprecipitation were
purchased from Upstate Biotech, NY, USA or Santa Cruz Biotech,
CA, USA. The anti-phosphotyrosine monoclonal antibody used for
Western analysis was from Upstate Biotech, NY, USA. The Super
Signal Chemiluminescent Substrate for the Western detection was
purchased from Pierce. HRP-conjugated goat anti-rabbit and anti-
mouse secondary antibodies and puri¢ed human plasma ¢brinogen
were purchased from Cal Biochem. Protein G- and protein A/G-con-
jugated agarose beads were from Santa Cruz and PVDF membrane
was from Millipore. Human K-thrombin was a gift from Dr. Frank
Church, University of North Carolina, Chapel Hill, NC, USA. ADP
was purchased from Chrono-log. All other chemicals were purchased
from Sigma.
2.2. Isolation and puri¢cation of human platelets
Platelets were puri¢ed as described [7] from whole blood of volun-
teers, who had abstained from using aspirin for at least 10 days. In
short, platelet-rich plasma was obtained by centrifugation of the col-
lected blood at 200Ug for 25 min at ambient temperature. Platelets
were pelleted from the supernatant by centrifugation at 800Ug for 20
min at ambient temperature. Platelets were resuspended in Tyrode’s
bu¡er, pH 7.2 (10 mM HEPES, 135 mM NaCl, 2.7 mM KCl, 12 mM
NaHCO3, 5.5 mM glucose, 2% (w/v) bovine serum albumin (fraction
V, Miles Pentex)) and passed through a Sepharose CL-2B column
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equilibrated with Tyrode’s bu¡er. The platelets were eluted in the
same bu¡er, were diluted to the desired concentration in Tyrode’s
bu¡er with 1 mM Ca2 and 2 mM Mg2 and maintained at 37‡C.
2.3. Platelet aggregation
Platelets were incubated at 37‡C at a ¢nal concentration of 1U108
platelets in 0.5 ml in cuvettes in a Chrono-log aggregometer. Aggre-
gation was initiated by stepwise addition of 300 nM human plasma
¢brinogen and agonist, 10 WM ADP or 0.5 units/ml thrombin, fol-
lowed by stirring. Aggregation was monitored as the increase in light
transmission [7], and the aggregation reaction was stopped by the
addition of 125 Wl ice cold 5U Triton lysis bu¡er (see below).
2.4. Preparation of Triton-soluble fractions and RIPA-soluble fractions
Triton-soluble fractions were prepared as modi¢ed from Clark et al.
[8] in lysis bu¡er containing 20 mM Tris-HCl, pH 7.4, 1% (v/v) Triton
X-100, 5 mM EGTA, 4 Wg/ml leupeptin, 100 Wg/ml PMSF, 4 Wg/ml
aprotinin and 1.2 mM sodium vanadate (1U). Unstimulated (platelets
incubated at 37‡C with no addition and no stirring) or aggregated
platelets (500 Wl) were added to 125 Wl ice-cold 5U lysis bu¡er, mixed
by gentle shaking and kept on ice for 1 h. For experiments with syk
and L3, 500 Wl contained 1U108 platelets and for experiments with
LAT, 500 Wl contained 2U108 platelets. The sample was centrifuged
at 15 000Ug for 10 min at 4‡C and the supernatant was collected; this
fraction is the Triton-soluble fraction which contains both the cyto-
plasmic and membrane-associated proteins. RIPA-soluble fractions
were prepared from the Triton-insoluble pellet, which was resus-
pended in 625 Wl of ice-cold 1U RIPA bu¡er containing 20 mM
Tris-HCl, pH 7.4, 158 mM NaCl, 0.1% (w/v) SDS, 1% (v/v) Triton
X-100, 1% (w/v) sodium deoxycholate, 1 mM EGTA, 4 Wg/ml leupep-
tin, 100 Wg/ml PMSF, 4 Wg/ml aprotinin and 1.2 mM sodium vana-
date. Samples were kept on ice for 1 h with occasional vortexing (at
least three times). After centrifugation at 15 000Ug for 10 min at 4‡C,
the supernatant was collected; this is the RIPA-soluble fraction which
contains the cytoskeletal proteins. All of the fractions were stored at
370‡C.
2.5. Jurkat T-cell extract preparation
Jurkat T cells were suspended at 1U108/ml concentration in RPMI
1640 media containing 10% FBS. One set was stimulated with 2 Wg/ml
CONA for 30 s. No addition was done in the unstimulated set. The
cells were centrifuged at 2000 rpm for 5 min, resuspended in 1 ml of
ice-cold lysis bu¡er containing 20 mM Tris-HCl, pH 7.4, 1% (v/v)
Triton X-100, 150 mM NaCl, 5 mM EGTA, 4 Wg/ml leupeptin, 100
Wg/ml PMSF, 4 Wg/ml aprotinin and 1.2 mM sodium vanadate and
kept on ice for 1 h with occasional vortexing. The lysates were cen-
tri¢uged at 10 000 rpm at 4‡C for 10 min. The supernatant was col-
lected and was frozen at 370‡C until use. 200 Wl of each lysate,
corresponding to 2U107 Jurkat T cells, was immunoprecipitated
with 4 Wg anti-LAT antibody as described below.
2.6. Immunoprecipitation
Triton-soluble fractions and RIPA-soluble fractions were thawed
on ice. Protein G agarose beads were used for LAT immunoprecipi-
tation. Protein A/G agarose beads were used for all other immuno-
precipitations. Beads were washed once with 1 ml ice cold 1U PBS.
Forty Wl of beads were added to each fraction and tumbled for 1 h at
4‡C. After centrifugation at 1000Ug for 20 s, the precleared super-
natant was collected. Primary antibody was added and the sample was
tumbled overnight at 4‡C. Washed beads (40 Wl) were added and the
sample was tumbled for 1 h at 4‡C. After centrifugation at 1000Ug
for 1 min, the supernatant was removed. The beads, which retain the
immunoprecipitate, were washed four times with 1 ml ice-cold 1U
lysis bu¡er. The washed beads were resuspended in 40 Wl 2U reducing
SDS-PAGE sample bu¡er, boiled for 5 min, centrifuged and the
supernatants were applied to SDS-PAGE gels [9]. For L3 immunopre-
cipitations (Fig. 3B), 7.5 Wg of an anti-L3 monoclonal antibody AP-3,
for syk immunoprecipitation (Fig. 3A), 1 Wg of a polyclonal antibody
(Santa Cruz) and for LAT immunoprecipitation (Figs. 1 and 3C), 4 Wg
of a polyclonal antibody (Upstate) was used.
2.7. Western blots
Samples in reducing SDS sample bu¡er were boiled for 5 min, run
on 10% SDS-PAGE for syk and L3 or 7.5% SDS-PAGE for LAT and
transferred to PVDF membrane. After blocking with 5% milk TBST
containing 50 mM Tris-HCl bu¡er, pH 7.4, 150 mM NaCl and 0.01%
Tween-20, the membrane was incubated overnight at 4‡C with the
primary antibody diluted in 3% milk in TBST. For phosphotyrosine
blot, the membrane was blocked with 10% BSA in TBST. After wash-
ing three times with TBST, the membrane was incubated for 1 h with
goat anti-rabbit secondary antibody conjugated to HRP at 1:25 000
dilution in 3% milk in TBST for LAT detection and at 1:10 000
dilution for syk and L3 detection. After washing three times with
TBST, the signal was developed with the Super Signal Chemilumines-
cent Substrate (Pierce) for 5 min. For syk immunodetection, 1 Wg/ml
of the anti-syk polyclonal antibody (Upstate), for L3 immunodetec-
tion, 10 Wg/ml of the polyclonal anti-L3 antibody [6] and for LAT
immunodetection, 1 Wg/ml of the anti-LAT polyclonal antibody (Up-
state) was used.
3. Results
3.1. Tyrosine phosphorylation of LAT in platelets
To show the presence and tyrosine phosphorylation of
LAT, we immunoprecipitated LAT from the Triton-soluble
fractions of ADP-stimulated and thrombin-stimulated plate-
lets under the conditions of aggregation and from unstimu-
lated platelets, and probed with an anti-phosphotyrosine anti-
body in an immunoblot. The results shown in Fig. 1A
demonstrate that the tyrosine phosphorylation of a 36^38-
kDa band was enhanced during ADP- (lane 2) and thrombin-
(lane 3) stimulated aggregation (compare with the unstimu-
lated sample in lane 1). These bands co-migrated with the
bands in lanes 4 and 5 which represent LAT immunoprecipi-
tates from Jurkat T cells. The tyrosine phosphorylation was
enhanced in lane 5 compared to lane 4 showing that stimula-
tion of T cell enhanced LAT tyrosine phosphorylation. The
blot was stripped and reprobed with the anti-LAT antibody.
Fig. 1B showed that the 36^38-kDa band in all lanes cross-
reacted with the anti-LAT antibody. The intensity of the band
is similar in lanes 1, 2 representing unstimulated and ADP-
stimulated platelets. The intensity in lane 3 was little less
which represents thrombin-stimulated platelets. These bands
co-migrated with the band in lanes 4 and 5, representing T
cells. The intensity of the bands in lane 4 was also similar to
that in lane 5. Data from Fig. 1 demonstrated that the tyro-
sine phosphorylation of LAT was enhanced during ADP- and
thrombin-stimulated aggregation (panel A), though the
amount of LAT present in unstimulated and ADP-stimulated
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Fig. 1. Tyrosine phosphorylation of LAT during platelet aggrega-
tion. Immunoprecipitates prepared with an anti-LAT polyclonal
antibody (panel A) were subjected to SDS-PAGE under reducing
condition. The blot in panel A was probed with an anti-phosphotyr-
osine monoclonal antibody. Platelets represent samples made from
platelets. The sample in lane U was from unstimulated platelets.
Stimulated platelet samples with 300 nM ¢brinogen were stirred for
20 s following addition of 10 WM ADP (lane marked +ADP), or
0.5 U/ml thrombin (lane marked +Thr). T cells represent samples
made from T cells. The sample in lane U was from unstimulated T
cells. T cells stimulated with 2 Wg/ml CONA for 30 s (lane marked
CONA). The blot in panel A was stripped and probed with the
anti-LAT polyclonal antibody (panel B).
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samples was similar (panel B, lanes 1 and 2) and little less in
the thrombin-stimulated sample (panel B, lane 3). Similar re-
sults were obtained with T cells (compare lanes 4 and 5 in
panel A and panel B).
3.2. Translocation pattern that distinguished ADP-stimulated
and thrombin-stimulated aggregation
ADP and thrombin stimulation led to reversible and irre-
versible aggregation, respectively. Representative aggregation
curves, shown in Fig. 2, showed that aggregation following
ADP stimulation reached a maximum at about 1 min and
then fell slowly, while aggregation following thrombin stimu-
lation progressed beyond 1 min. The reversible nature of
ADP-stimulated aggregation suggests that the cytoskeleton
is not permanently rearranged during this process. Since other
signaling molecules implicated in platelet aggregation are
known to di¡erentially translocate during ADP-stimulated re-
versible and thrombin-stimulated irreversible aggregation [3],
we examined the translocation of LAT to the cytoskeleton
after stimulation with each agonist. We further examined
the translocation of syk and L3 to the cytoskeleton. Syk and
L3 are known to translocate to the cytoskeleton during throm-
bin-stimulated irreversible aggregation [1]; however, it is not
known whether they translocate to the cytoskeleton during
ADP-stimulated reversible aggregation.
Samples were prepared, terminating aggregation with the
addition of Triton lysis bu¡er after 20 s and 2 min, time
points chosen to distinguish early and late aggregation. In-
soluble material was removed from Triton lysates by centri-
fugation, and a RIPA-soluble fraction was prepared from the
pellet, as described in Section 2. Both Triton-soluble and
RIPA-soluble fractions were immunoprecipitated with a poly-
clonal antibody to syk and the immunoprecipitates were an-
alyzed with a di¡erent polyclonal anti-syk antibody (see Sec-
tion 2). As shown in Fig. 3A, a 72-kDa band corresponding to
syk was seen in all Triton-soluble fractions (lanes 1^5). In
contrast, syk was seen in the RIPA-soluble fractions only
when platelets were stimulated with thrombin (lane 10), at a
late stage of platelet aggregation (2 min). Interestingly, syk
was not seen in the RIPA-soluble fraction from ADP-stimu-
lated aggregation even at 2 min (lane 8).
To examine the distribution of L3 in these samples, we
immunoprecipitated L3 from the lysates described in Fig.
3A. The immunoblot was probed with a polyclonal antibody
to L3. As shown in Fig. 3B, a band around 110 kDa corre-
sponding to L3 was observed in all Triton-soluble fractions
(lanes 1^5). In the RIPA-soluble fractions, L3 was only de-
tected in the sample prepared 2 min after thrombin-stimulated
aggregation (lane 10).
Similarly, to examine the distribution of LAT in Triton-
and RIPA-soluble fractions, we immunoprecipitated LAT.
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Fig. 3. Distribution of syk, L3 and LAT following ADP- and
thrombin-stimulated aggregation. Triton-soluble and RIPA-soluble
samples after 20 s and 2 min of aggregation were immunoprecipi-
tated with a polyclonal antibody to syk (panel A), with a monoclo-
nal antibody to L3 (panel B), or a polyclonal antibody to LAT
(panel C). The immunoprecipitates were subjected to reducing SDS-
PAGE and probed with a polyclonal antibody to syk (panel A),
with a polyclonal antibody to L3 (panel B), or with a polyclonal
antibody to LAT (panel C). Samples in lanes U were from unstimu-
lated platelets. Stimulated platelet samples with 300 nM ¢brinogen
were stirred for 20 s or 2 min following addition of 10 WM ADP
(lanes marked +ADP), or 0.5 U/ml thrombin (lanes marked +Thr).
TSF: Triton-soluble fractions. RSF: RIPA-soluble fractions.
Fig. 2. ADP- and thrombin-stimulated reversible and irreversible ag-
gregation of platelets. Platelets (2U108/ml) were incubated at 37‡C
with 300 nM ¢brinogen and aggregation was initiated with either 10
WM ADP or 0.5 units/ml thrombin; additions are indicated by the
arrows. Aggregation of stirred samples was measured as an increase
in light transmission.
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The immunoblot was probed with a polyclonal antibody to
LAT. As shown in Fig. 3C, a band around 36^38 kDa corre-
sponding to LAT was observed in all Triton-soluble fractions
(lanes 1^5). In the RIPA-soluble fractions, LAT was only
detected in the sample prepared 2 min after thrombin-stimu-
lated aggregation (lane 10).
Thus the distribution of LAT correlated with the distribu-
tion of syk and L3 (Fig. 3A, B and C). These data demon-
strate that LAT, syk and L3 translocate to the cytoskeleton in
the later phase of aggregation (2 min) in response to throm-
bin-stimulated irreversible aggregation, but not in response to
ADP-stimulated reversible aggregation.
4. Discussion
In this study we have documented the presence of LAT in
platelets. LAT was tyrosine phosphorylated when platelets
were stimulated with either ADP or thrombin in the presence
of ¢brinogen under aggregation conditions (Fig. 1). Phos-
phorylation of LAT during platelet aggregation indicates
that LAT might be important in platelet signaling. Since
LAT is a substrate of syk in T cells, it will be interesting to
determine if LAT is a substrate of syk in platelets. Syk tyro-
sine kinase has been implicated to play a major role in platelet
aggregation as syk 3/3 mouse platelets aggregate abnormally
[10] and syk 3/3 mice die perinatally due to internal hemor-
rhaging [11,12]. Further, we have evidence that syk associates
with the L3 subunit of KIIbL3 in platelets [13]. Further studies
will be necessary to ¢nd out whether LAT carries the down-
stream signaling message starting from L3 and mediated
through syk.
The translocation pattern of LAT was similar to that of L3
and syk (Fig. 3). None of these molecules translocated to the
cytoskeleton during ADP-stimulated reversible and at the
early stage (20 s) of thrombin-stimulated irreversible aggrega-
tion. On the other hand, all of them translocated at the late
stage (2 min) of thrombin-stimulated aggregation. In a recent
study, it has been shown that the p85 subunit of PI3kinase-K
translocates to the cytoskeleton in response to thrombin-
stimulated aggregation with the production of phosphatidyl
(3,4)-bisphosphate and phosphatidyl-inositol (3,4,5)-P3 [3].
LAT associates with the p85 subunit of PI3kinase in T cells
[2]. It will be interesting to examine whether there is any func-
tional link between L3, syk and LAT with PI3kinase-K and
RhoA during permanent rearrangement of the cytoskeleton in
response to thrombin-stimulated aggregation.
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